IndustryCompany release

Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer

🇺🇸 Viatris Inc (VTRS) · Tue 17 Nov 2026

Viatris has closed its purchase of non-opioid pain company Pacira, with about 66.46% of shares tendered, and expects $90-100 million in revenue by year-end.

Viatris announced on 17 November 2026 that it has completed its acquisition of Pacira BioSciences, a company focused on non-opioid pain management. The deal followed a tender offer at $36.50 per share in cash.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Viatris Inc ↗

Article written by VigiEye from the official source (Viatris Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →